ArticleBiochemistry and biophysics reports2026
The role of nasal microbiota and type 2 innate lymphoid cells in the pathogenesis of allergic rhinitis.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is a type 2 inflammation-related disease, potentially associated with innate lymphoid cells (ILC2s), nasal microbiota, and autophagy. Mice were divided into control, AR, AR + IL-33, and AR + antibiotic groups(n = 5). ELISA was used to measure IL-4, IL-5, and IL-13, Masson staining to evaluate tissue remodeling, flow cytometry to detect ILC2s and memory ILC2s, 16S rRNA sequencing to analyze nasal microbiota, and Western blot to assess autophagy and mitophagy proteins. Compared with controls, mice in each AR group exhibited more nasal symptoms, enhanced tissue remodeling, and altered microbiota diversity with reduced Proteobacteria and increased Firmicutes. IL-33 further elevated type 2 cytokines in serum and nasal lavage fluid, increased nasal ILC2s and miR-155 expression, but did not affect memory ILC2s. All treatment groups showed increased p62 and LC3II/LC3I ratio, along with decreased FUNDC1 and BNIP3L levels. These findings suggest that AR is characterized by type 2 inflammation, tissue remodeling, and microbial dysbiosis, with IL-33 aggravation. Autophagy and mitophagy dysfunction may contribute to AR pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.